Decreased SFRP5 Correlated With Excessive Metabolic Inflammation in Polycystic Ovary Syndrome Can Be Reversed by Metformin: A Retrospective Case-Control Study

Yi Zhang
NHC Key Laboratory of Birth and Reproductive Health, Chongqing Population and Family Planning Science and Technology Research Institute

Yuxin Ran
The First Affiliated Hospital of Chongqing Medical University

Lingna Kong
The First Affiliated Hospital of Chongqing Medical University

Lihong Geng
The First Affiliated Hospital of Chongqing Medical University

Hua Huang
NHC Key laboratory of birth defects and reproductive health, Chongqing population and family planning science and technology research institute

Hongying Zhang
The First Affiliated Hospital of Chongqing Medical University

Jun Hu
The First Affiliated Hospital of Chongqing Medical University

Hongbo Qi
The First Affiliated Hospital of Chongqing Medical University

Ying Chen (chenying@cqmu.edu.cn)
The First Affiliated Hospital of Chongqing Medical University

Research

Keywords: Polycystic ovary syndrome (PCOS), Secreted frizzled-related protein (SFRP) 5, Inflammation, Metformin, Hyperandrogenism (HA)

DOI: https://doi.org/10.21203/rs.3.rs-143360/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Polycystic Ovary Syndrome (PCOS) is a complex endocrine disorder of heterogeneous nature. Secreted frizzled-related protein (SFRP) 5 is an anti-inflammatory adipokine implicated in metabolic homeostasis. We aimed to confirm the correlation between SFRP5, metabolic inflammation and PCOS, investigate the predictive value of SFRP5 for PCOS and the involvement of SFRP5 in metformin treated PCOS.

**Methods:** This retrospective case-control study included PCOS and control women (67 vs. 33) for detecting serum SFRP5 and its correlation with metabolic inflammation. Predictive value of SFRP5 for PCOS was evaluated by logistic regression and receiver operating characteristic (ROC) analyses. The effects of metformin on SFRP5 and pro-inflammatory cytokines and ovulation of PCOS with metabolic abnormality (37 vs. 36) were analysed.

**Results:** Plasma SFRP5 levels were decreased in PCOS (odds ratio: 0.78, 95% confidence interval (CI): 0.703–0.866, \( P < 0.001 \)) independent of obesity. SFRP5 was negatively associated with IL-6, TNFα, FAI and HOMA-IR. The cut-off point of SFRP5 < 46.13 ng/ml was optimal to identify PCOS with a higher specificity of 96.87% and a relatively lower sensitivity compared to AMH. SFRP5 increased specificity of AMH for predicting PCOS, especially which with relatively decreased AMH (< 4.7 ng/ml). Metformin promoted SFRP5 and decreased leptin, IL-6 and TNFα secretion in PCOS women with metabolic abnormality in a time dependent manner and with improved ovulation rate and pregnancy outcomes.

**Conclusion:** Decreased SFRP5 was associated with metabolic inflammation in PCOS and has a potential role for the supplement of AMH in predicting PCOS. The reverse of serum SFRP5 by metformin indicated that SFRP5 participated in the improvement of follicular development by metformin. Further prospective investigations are needed to confirm these preliminary data.

**Background**

Polycystic ovary syndrome (PCOS) is a complex endocrine disorder characterized by oligo-anovulation (OA), polycystic ovarian morphology (PCOM), hyperandrogenism (HA) and accompanied by metabolic aberrations (adverse lipid profile, impaired glucose tolerance (IGT), insulin resistance (IR) and type 2 diabetes mellitus (T2DM)). The prevalence of PCOS varies from 6% to 10% according to different diagnostic criteria, making PCOS the most common endocrine disorder among women of reproductive age [1].

The limited knowledge of its etiology and the heterogeneous nature make the definition, diagnostic criteria and treatment of PCOS to be controversial issues for many years [2-3]. Approximately half of the PCOS women exhibit obesity. Besides, about 30 to 50% of lean PCOS women still have an increased risk of metabolic abnormalities [4, 5]. In addition, there are also a portion of PCOS women without abnormal glycolipid metabolism exhibiting HA and ovarian dysfunction. Although biomarkers such as anti-
Müllerian hormone (AMH) have been suggested for diagnosis of PCOS, none of them could be used independently [6]. Appropriate recognition and management of PCOS remain challenges.

Increasing evidence supports that chronic low-grade inflammation correlates with HA and IR and emerges as a key contributor to the pathogenesis of PCOS [7]. Secreted frizzled-related protein (SFRP) 5, a member of the Wnt inhibitor SFRP family, is recently identified as an anti-inflammatory adipokine implicated in metabolic homeostasis [8]. Wnt signaling plays critical role in reproduction especially in the regulation of follicle maturation and is involved in the pathogenesis of PCOS [9-10]. SFRP5 is found related to the maturation of oocytes and regulation of granulosa cells [11]. Metformin is extensively evaluated in the treatment of PCOS because of its insulin-lowering effect. Moreover, it can also relieve chronic low-grade inflammation, inhibit ovarian steroidogenesis (including androgen production), and increase ovulation rate of PCOS women [12-15]. However, few studies supported the relationship between SFRP5 and PCOS[16-17]. The correlation of SFRP5 and metabolic inflammation in metformin treated PCOS women is unclear.

The purpose of this study was to confirm the correlation of SFRP5, metabolic inflammation and PCOS, investigate the predictive value of SFRP5 for PCOS. More importantly, we evaluated the effect of metformin on SFRP5, pro-inflammatory cytokines and ovulation rate in PCOS women with metabolic abnormalities to disclose the role of SFRP5 in metabolic inflammation of PCOS.

**Methods**

**Study participants**

This retrospective study included PCOS and control women of Chinese Han population visiting the reproductive medical center of the First Affiliated Hospital of Chongqing Medical University from January to July 2018. PCOS patients fulfilled the Rotterdam criteria containing at least two of the following three characteristics: (1) OA, (2) clinical and/or biochemical signs of HA, and (3) PCOM. Exclusion criteria were other etiologies for HA. Women with regular menstrual cycles were recruited as the controls. None of them had any known disease, were smokers or took any hormonal or other insulin-modifying therapy during the preceding 2 months. The PCOS women were divided into two subgroups according to the thresholds of body mass index (BMI) and AMH [6] indicated by previous studies: (1) BMI <25 and BMI ≥25; (2) AMH < 4.7 ng/ml and AMH ≥4.7 ng/ml. The serum level of SFRP5 and anthropometric and biochemical parameters of PCOS were detected and their association were analysed.

The other PCOS women complicated with IGT/IR and without other infertile factors and accepted no treatment in the previous six months were included for analyzing the role of SFRP5 in metformin treated PCOS and were divided into two groups. Group I was pretreated with metformin (1,000-1,500 mg/day; Conquer, Chongqing, China) for at least three months. Group II accepted no metformin treatment. Both groups were treated with clomiphene (150 mg/day for 5 consecutive days on menstrual cycle day 5; Codal-Synto, Limassol, and Cyprus). Human chorionic gonadotropin (hCG), 10,000 U (Livzon, Zhuhai, China) was administered intramuscularly whenever the diameter of the dominant follicle reached ≥18
mm and the estradiol level reached 150–200 pg/mL/follicle. Regular sexual intercourse was advised 24 h after the hCG day and afterward. If there were more than 3 dominant follicles, contraception was requested. The ovulation rates per cycle, days for follicular development, endometrial thickness, number of dominant follicles (>14 mm), serum estradiol on the day of HCG, accumulated HCG positive rate, accumulated clinical pregnancy rate, miscarriage rate and multiple pregnancy rate were investigated.

**Anthropometric and biochemical measurements**

Plasma glucose and hemoglobin A1c (HbA1c) levels were measured by the glucose-oxidase method and anion-exchange high-performance liquid chromatography, respectively. Total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides (TGs), and low-density lipoprotein cholesterol (LDL-C) were determined enzymatically using an auto analyzer (Hitachi, Tokyo, Japan). Serum insulin, total testosterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH) and sex hormone-binding globulin (SHBG) levels were assayed by an automated chemiluminescence system on the UniCel Dxl 800 (Beckman Coulter, Fullerton, CA, USA) between day 2 and 5 of the menstrual cycle. Insulin resistance index (HOMA-IR) and Free androgen index (FAI) were calculated as following respectively: fasting glucose \([\text{mmol} \text{L}^{-1}]\) * fasting insulin [IU/mL]/22.5 and testosterone (nmol/L) × 100/SHBG (nmol/L). The area under the curve of glucose (AUCG) and the area under the curve of insulin (AUCI) were calculated for detailed analysis of the OGTT (AUCG= (G0+G3)/2+G1+G2 and AUCI= (I0+I3)/2+I1+I2).

**Oral glucose tolerance test (OGTT)**

The baseline blood samples were obtained after an overnight fasting of 12 h. Then blood samples were obtained at 0.5, 1 and 2 h for the measurements of glucose and insulin after drinking 75 g of glucose.

**Measurement of human SFRP5, TNFα, IL-6 and leptin serum concentrations**

Fasting blood samples were analyzed for SFRP5, TNFα, IL-6 and leptin after 0, 1 and 3 months of metformin treatment in Group I using enzyme-linked immunosorbent assays (ELISAs) (USCN Life Science and CUSABIO, Wuhan, PR China) with a sensitivity of 0.60 ng/ml, 1.95 pg/ml, 1.95 pg/ml and 0.06 ng/ml, respectively.

**Statistical analysis**

All statistical analyses were performed using SPSS 19.0 software (SPSS Inc., Chicago, IL, USA) and MedCalc 18.11.3 software (Acacaliaan, Ostend, Belgium). Normally and non-normally distributed continuous data are presented as the mean±standard deviation (SD) or medians (25th and 75th percentiles). Subjects with missing data were excluded. For normally distributed continuous data, comparisons among groups were performed by ANOVA and an unpaired t test as appropriate. For nonnormally distributed continuous data, we used Kruskal-Wallis ANOVA followed by pairwise comparisons or a Mann-Whitney U test to compare differences in the variables in normal controls and different PCOS subgroups and a Dunn-Bonferroni test for post hoc comparisons. Partial correlations
between SFRP5 and other variables were calculated by controlling for the covariates. Simple and multivariable linear regression analyses examined the associations of SFRP5 with other variates. Stepwise logistic regression analyses were adjusting for age, BMI, AMH, AUCg, AUCins, HOMA-IR and FAI were conducted to assess the effects of SFRP5 in the diagnoses PCOS. The variables were log transformed to conform to normal distribution assumptions. The Box-Tidswell transformation \((x \cdot \ln(x))\) of the predictor \(x\) was used to assess the linearity in the logit. A receiver operating characteristic (ROC) analysis was performed to assess the diagnostic value of SFRP5 as a marker of PCOS. The maximum Youden index was used to determine the optimal sensitivity and specificity, as well as the corresponding cut-off value. \(P\) values of less than 0.05 were considered statistically significant.

**Results**

1. **Circulating SFRP5 levels and its association with clinical and biochemical characteristics in PCOS**

A total of 91 PCOS patients and 108 control women satisfied the inclusion criteria. However, only 67 PCOS and 33 control women with consent and available blood samples were enrolled. Thirty-one of PCOS were with PCOM, HA and OA, twenty-three with HA and OA and thirteen with PCOM and OA.

As displayed in Table 1, serum SFRP5 were significantly lower in PCOS women, \(P<0.001\). Instead, the levels of BMI, waist hip ratio (WHR), fasting blood glucose (FBG), fasting insulin (FINS), 2 hour blood glucose and insulin, AUCG, AUCI, HOMA-IR, HbA1c, TG, AMH, FAI, IL-6 and TNF\(\alpha\) \((P<0.001)\); TC \((P=0.007)\); HDL-C \((P=0.022)\) and LH \((P=0.023)\) were significantly higher in PCOS women.

No obvious difference of SFRP5 level was found between normal weight (BMI<25) and overweight/obese (BMI \(\geq\) 25) PCOS patients, although BMI, WHR, HOMA-IR and FINS levels were significantly higher in the latter. Furthermore, SFRP5 was still lower in normal-weight PCOS patients than BMI-matched control patients, \(P<0.001\).

After adjusting for age, BMI and WHR, partial correlations disclosed negative correlations of serum SFRP5 with FAI, FBG, IL-6 and TNF\(\alpha\) \((P<0.001)\), AMH \((P=0.005)\), 2-h BG \((P=0.007)\) and HOMA-IR \((P=0.028)\) (Table 2). Multiple linear regression analysis suggested SFRP5 was only significantly correlated with FAI \((P=0.041)\), IL-6 \((P=0.046)\) and TNF\(\alpha\) \((P=0.033)\) (Table 3).

2. **The predictive value of SFRP5 for the diagnosis of PCOS**

Multivariate logistic regression analysis indicated decreased plasma SFRP5 levels were associated with an increased incidence of PCOS (OR: 0.818, 95% confidence interval (CI):0.691-0.968, \(P=0.019\)) (Table 4). The cut-off point of SFRP5 was 46.13 ng/ml with a sensitivity of 88.06% and a higher specificity of 96.87% (AUC: 0.960, 95% CI: 0.900-0.989, \(P<0.0001\)). The cut-off point of AMH was 3.23 ng/ml with a sensitivity of 98.51% and a specificity of 90.62% (AUC: 0.968, 95% CI 0.912-0.993, \(P<0.0001\)). Combination of SFRP5 and AMH improved the specificity to 100% and still with a sensitivity of 91.04% (AUC: 0.980, 95% CI: 0.930-0.998, \(P<0.0001\)) (Figure 1).
For women with a lower AMH level (<4.7 ng/ml, N=23), SFRP5 was still predictive of PCOS (OR: 0.818, 95% CI: 0.692-0.968, P=0.019) (Table 4). The cut-off point of SFRP5 was 42.69 ng/ml with a higher specificity of 96.97% and a sensitivity of 82.61% (AUC: 0.955, 95% CI 0.864-0.992, P<0.0001) (Figure 2).

3. Metformin promoted SFRP5 and decreased leptin, IL-6 and TNFα protein secretion in PCOS women with metabolic abnormalities

There was no difference of baseline demographic and clinical characteristics between Group I (N=37) and Group II (N=36) (Table 5). After treated with metformin for 1 and 3 months, serum SFRP5 of Group I significantly increased than that before administration (45.60±8.148 and 63.92±8.24 vs 32.16±5.71 ng/ml, P<0.001). Conversely, the secretion of leptin, IL-6 and TNFα were decreased after 1 and 3 months’ treatment (P<0.001) (Figure 3).

4. Pretreatment with metformin had a positive effect on the ovulation rate and pregnancy outcomes of PCOS women with metabolic abnormalities

Before clomiphene treatment, the parameters of glucose metabolism in Group I were all adjusted to normal by metformin (data not shown). The ovulation rate, number of dominant follicles (P<0.001), serum estradiol level on the day of HCG administration and accumulated clinical pregnancy rate (P<0.05) in Group I was significantly higher than that of Group II. The duration for follicular development in Group I was significantly shorter than that of Group II (P<0.01). There was no statistical significance in endometrial thickness, accumulated HCG positive rate and miscarriage rate between the two groups (Table 6).

Discussion

As an anti-inflammatory adipokine, SFRP5 has been identified implicated in metabolic homeostasis. In this study, SFRP5 levels were negatively associated with incidence of PCOS, HA, IR and inflammation independent of obesity. Plasma SFRP5 level might have a potential role for the supplement of AMH in predicting PCOS. Metformin promoted SFRP5 protein secretion and decreased pro-inflammatory factors in PCOS women with improved ovulation rate and pregnancy outcomes.

Consistent with the findings of Hu, we found serum SFRP5 levels were decreased in PCOS in Chinese population [17], which was opposite to the findings of Almario in American population [16]. One difference was that we used Rotterdam criteria to include PCOS women, whereas Almario used the NIH criteria. The other difference was that the reference women reported by Almario were fatter (BMI: 29.0 ± 6.3 kg/m²) than our Chinese controls (BMI: 20(19.8, 21)). And they were older and with higher cholesterol level than their PCOS women. Because Chinese women have an increased risk of metabolic problems at a low BMI (≥24) [18], the control women included in our study have a relatively lower BMI. As BMI can not discriminate between fat mass and muscle mass and cannot represent abdominal adiposity, we detected WHR and found no relationship between SFRP5 and WHR. Consistent with the findings of Almario and other study [19], serum SFRP5 level was independent of obesity. Intensive exploration showed SFRP5
conditionally exerted an anti-inflammatory effect in response to an obesity-associated microenvironment. So the microenvironment rather than the mass of adipocytes plays a more important role in the regulation of SFRP5.

We detected higher level of IL-6 and TNF-α and FAI in PCOS, which were correlated with SFRP5. Inflammation is closely interrelated with HA in ovarian microenvironment. HA stimulated cumulus cells secreting more inflammatory cytokines as well as oocyte maturation. In turn, the direct exposure of ovarian theca cells to pro-inflammatory stimuli also increases androgen production [20]. Our findings suggest SFRP5 is involved in the interaction of inflammations and HA. We demonstrated that FINS, 2-h INS, AUCI and HOMA-IR were significantly higher in PCOS, which indicated the association of IR and PCOS. Moreover, 2-h INS and 2-hBG were higher in normal-weight PCOS women than normal control indicating the metabolic aberration independent of obesity in PCOS. Serum SFRP5 was negatively correlated with FINS, 2-h INS, AUCI and HOMA-IR. The negative correlation between SFRP5 and IR has been determined in T2DM patients and animal models [21]. Caloric restriction improved insulin sensitivity and was associated with a significant increase of SFRP5. Proinflammatory cytokines and mediators closely correlate with insulin resistance through interfering with insulin signal transduction. Whether SFRP5 responds to hyperinsulinemia or the inflammatory conditions accompanied with IR need to be considered.

AMH, correlating with PCOM, has been proposed as a biomarker for the diagnosis of PCOS. However, AMH can be influenced by HA, obesity and inflammation. Moreover, the conflicting results of AMH's effect on the growth of primordial follicles [22] and the heterogeneity of the PCOS phenotypes led to current controversy on the value of AMH for predicting PCOS among an unselected group of women. Our results suggest that SFRP5 could predict PCOS with a higher specificity in total PCOS population. However, the sensitivity of SFRP5 was lower than AMH. Combination of AMH and SFRP5 improved the sensitivity and specificity of the two biomarkers individually. In the subgroup of PCOS with lower AMH (< 4.7 ng/ml), SFRP5 still had a higher specificity. We proposed that SFRP5 worked as a specific biomarker for PCOS as complement to AMH especially in phenotype without PCOM.

The current therapeutic options for infertile PCOS women using clomiphene citrate (CC) et al are always associated with drug resistance, especially in PCOS women with metabolic abnormalities. The effects of metformin on PCOS related IR, inflammation, ovarian steroidogenesis and ovulation have been confirmed. We found that metformin promoted SFRP5 protein secretion and decreased leptin, IL-6 and TNFα protein secretion of PCOS women in a time dependent manner. Meanwhile, our results identified that metformin combined with CC had positive effects on the ovulation rate and pregnancy outcomes of PCOS women with metabolic abnormalities. Accordingly, a similar conclusion was drawn in the 2017 Cochrane Review [23]. Our results suggest that SFRP5 related anti-inflammatory process is involved in the improvement of ovulation of PCOS by metformin.

Conclusions
SFRP5 was decreased in PCOS and associated with metabolic inflammation. SFRP5 has a potential role for the supplement of AMH in predicting PCOS. SFRP5 participates in the anti-inflammatory effect of metformin in improving follicular development. As this is a retrospective study with limited cases, a well-designed randomized controlled intervention trial is required to eliminate potential bias. And the molecular mechanism of SFRP5’s anti-inflammatory role in PCOS should be further investigated in vitro and in animal model.

**Abbreviations**

PCOS Polycystic Ovary Syndrome  
SFRP Secreted frizzled related protein  
ROC Receiver operating characteristic  
HA Hyperandrogenism  
OA Oligo-anovulation  
PCOM Polycystic ovarian morphology  
IGT Impaired glucose tolerance  
IR Insulin resistance  
T2DM Type 2 diabetes mellitus  
BMI Body mass index  
HCG Human chorionic gonadotropin  
HbA1c Hemoglobin A1c  
HDL-C High-density lipoprotein cholesterol  
TG Triglyceride  
LDL-C Low-density lipoprotein cholesterol  
FSH Follicle-stimulating hormone  
LH Luteinizing hormone  
SHBG Sex hormone-binding globulin  
HOMA-IR Insulin resistance index
FAI Free androgen index
AUCG Area under the curve of glucose
AUCI Area under the curve of insulin
OGTT Oral glucose tolerance test
ELISA Enzyme-linked immunosorbent assay
SD Standard deviation
WHR waist hip ratio

**Declarations**

**Authors' contributions**

Ying Chen and Hongbo Qi designed the research. Yi Zhang and Yuxin Ran contributed in patient selection, data collection, interpretation of data and manuscript writing/editing. Lihong Geng, Hongying Zhang and Jun Hu contributed in patient selection and data collection. Lingna Kong and Hua Huang assisted in the analysis of the data. All authors read and approved the final manuscript.

**Funding**

This work was supported by Chongqing Science and Technology Bureau (No. cstc2019jcyj-msxmX0817), Joint Medical Research Project of Chongqing Health Commission (No.2019MSXM060, 2018MSXM070), Chongqing Population and Family Planning Science and Technology Research Institute (No.cstc2018jxjl130020, cstc2018jxjl130053) and Foundation of Reserving Personnel of Academic Leaders of the First Affiliated Hospital of Chongqing Medical University.

**Availability of data and materials**

The data generated during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

Ethical approval was granted by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University (No.2018-071). Informed consent was obtained from all women.

**Consent for publication**

All patients gave written informed consent for publication.

**Competing interests**
The authors declare that they have no competing interests.

References

1. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016; 31(12):2841-2855

2. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016; 37(5):467-520.

3. Rosenfield RL. The Diagnosis of Polycystic Ovary Syndrome in Adolescents. Pediatrics. 2015; 136(6):1154-1165.

4. Marciniak A, Nawrocka Rutkowska J, Brodowska A, Wiśniewska B, Starczewski A. Cardiovascular system diseases in patients with polycystic ovary syndrome - the role of inflammation process in this pathology and possibility of early diagnosis and prevention. Ann Agric Environ Med. 2016; 23(4):537-541.

5. Tahergorabi Z, Salmani F, Jonaidabad SH, Behdani B, Yazdi P, Zardast M, Moodi M. Association of serum levels of vascular endothelial growth factor and thrombospondin-1 to body mass index in polycystic ovary syndrome: a case-control study. Obstet Gynecol Sci. 2019; 62(6):420-428.

6. Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab. 2013; 98(8):3332-3340.

7. Spritzer PM, Lecke SB, Satler F, Morsch DM. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction. 2015; 149(5):R219-227.

8. Ouchi N, Higuchi A, Ohashi K, Oshima Y, Gokce N, Shibata R, et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science. 2010; 329(5990):454-457.

9. Hernandez Gifford JA. The role of WNT signaling in adult ovarian folliculogenesis. Reproduction. 2015; 150(4):R137-148.

10. Zhao Y, Zhang C, Huang Y, Yu Y, Li R, Li M, Liu N, Liu P, Qiao J. Up-regulated expression of WNT5a increases inflammation and oxidative stress via PI3K/AKT/NF-κB signaling in the granulosa cells of PCOS patients. J Clin Endocrinol Metab. 2015; 100(1):201-211.

11. Maman E, Yung Y, Cohen B, Konopnicki S, Dal Canto M, Fadini R, Kanety H, Kedem A, Dor J, Hourvitz A. Expression and regulation of sFRP family members in human granulosa cells. Mol Hum Reprod. 2011; 17(7):399-404.

12. Jing Y, Wu F, Li D, Yang L, Li Q, Li R. Metformin improves obesity-associated inflammation by altering macrophages polarization. Mol Cell Endocrinol. 2018;461:256-264.

13. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med.
14. Kurzthaler D, Hadziomerovic-Pekic D, Wildt L, Seeber BE. Metformin induces a prompt decrease in LH-stimulated testosterone response in women with PCOS independent of its insulin-sensitizing effects. Reprod Biol Endocrinol. 2014;12:98. Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org; Practice Committee of the American Society for Reproductive Medicine.

15. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertil Steril. 2017;108(3):426-441.

16. Almario RU, Karakas SE. Roles of circulating WNT-signaling proteins and WNT-inhibitors in human adiposity, insulin resistance, insulin secretion, and inflammation. Horm Metab Res. 2015; 47(2):152-157.

17. Hu W, Li L, Yang M, Luo X, Ran W, Liu D, Xiong Z, Liu H, Yang G. Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans. J Clin Endocrinol Metab. 2013; 98(1):290-298.

18. Cooperative Meta-Analysis Group of China Obesity Task Force. Predictive values of body mass index and waist circumference to risk factors of related diseases in Chinese adult population [Chinese]. Chin J Epidemiol. 2002; 23:5-10.

19. Schulte DM, Müller N, Neumann K, Oberhäuser F, Faust M, Güdelhöfer H, Brandt B, Krone W, Laudes M. Pro-inflammatory wnt5a and anti-inflammatory sFRP5 are differentially regulated by nutritional factors in obese human subjects. PLoS One. 2012; 7(2):e32437.

20. Lima PDA, Nivet AL, Wang Q, Chen YA, Leader A, Cheung A, Tzeng CR, Tsang BK. Polycystic ovary syndrome: possible involvement of androgen-induced, chemerin-mediated ovarian recruitment of monocytes/macrophages. Biol Reprod. 2018; 99(4):838-852.

21. Cheng L, Zhang D, Chen B. Declined plasma sfrp5 concentration in patients with type 2 diabetes and latent autoimmune diabetes in adults. Pak J Med Sci. 2015; 31(3):602-605.

22. Schmidt KL, Kryger-Baggesen N, Byskov AG, Andersen CY. Anti-Müllerian hormone initiates growth of human primordial follicles in vitro. Mol Cell Endocrinol. 2005; 234(1-2):87-93.

23. Morley LC, Tang T, Yasin E, Norman RJ, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2017; 11:CD003053.

**Tables**

**TABLE 1** Comparison of main clinical features in normal controls and PCOS subjects
| Item          | Normal control | PCOS                      | Normal weight (BMI<25) | Overweight /Obese (BMI≥25) | P-value |
|--------------|----------------|---------------------------|------------------------|-----------------------------|---------|
| N            | 33             | 33                        | 34                     |                              |         |
| SFRP5 (ng/ml)| 64.25(52.64, 72.26) | 36.63(32.74, 43.31)c      | 35.38(30.01, 38.31)c   |                              | 0.001   |
| Age (years)  | 29(27, 31)     | 27(25, 29)                | 28(27, 32)             |                              | 0.293   |
| BMI (Kg/m²)  | 20(19.8,21)    | 21.4(20,23.6)             | 27.79 (26.8,29.05)c,f  |                              | 0.001   |
| WHR          | 0.78(0.76,0.81)| 0.79(0.76, 0.82)          | 0.833(0.82, 0.85)c,f   |                              | 0.001   |
| AMH (ng/ml)  | 2.9(2.3,3.04)  | 5.5 (4.2,5.9)c            | 5.45(4.53, 8.3)c       |                              | 0.001   |
| FSH (mIU/ml) | 7.4(6.5,8.54)  | 5.66(5.12,7.49)a          | 6.88(5.45,8.61)        |                              | 0.036   |
| LH (mIU/ml)  | 7.4(5.4,8.6)   | 9.12(6.6,12)a             | 6.7(5.4, 11.01)        |                              | 0.023   |
| FAI          | 2.19(1.79,2.63)| 6.00(4.38, 7.55)c         | 6.54(4.74,8.43)c       |                              | 0.001   |
| FINS (Uiu/ml)| 5.4(4.3,6.5)   | 5.97(4.85, 9.15)          | 12.99(10.83,14.85)c,f  |                              | 0.001   |
| 2-h INS (Uiu/ml) | 18.5(13.22,27.87) | 41.2 (33.94,81.95)c       | 99.49(67.99,138.86)c,e  |                              | 0.001   |
| FBG (mmol/l) | 4.9(4.8,5.1)   | 5.3 (5.1,5.6)c            | 5.65 (5.3, 5.9)c       |                              | 0.001   |
| 2-hBG (mmol/l) | 5.8(5.1,6.4)   | 7.2 (6.4,8.8)c            | 8.9(7.33, 10.65)c      |                              | 0.001   |
| TG (mmol/L)  | 0.98(0.86,1.1) | 1.03(0.76, 1.55)          | 2.1(1.6,2.98)c,f       |                              | 0.001   |
| TC           | 4.3(4.02,4.65) | 4.5 (4.2,4.9)             | 4.8(4.53,5.09)b        |                              | 0.007   |
|                | Study Population | Control | P value |
|----------------|------------------|---------|---------|
| **HDL-C (mmol/L)** | 1.32 (1.23, 1.54)  | 1.26 (1.12, 1.38) | 1.25 (1.04, 1.41) | 0.022 |
| **LDL-C (mmol/L)**  | 2.6 (2.4, 2.8)    | 2.6 (2.3, 2.78) | 2.85 (2.70, 3.86) | 0.056 |
| **HbA1c (%)**      | 5.4 (5.2, 5.5)    | 5.6 (5.4, 5.7)  | 5.7 (5.5, 6.0)    | 0.001 |
| **AUCI**           | 75.66 (66.1, 88.95) | 148.82 (106.4, 255.49) | 265.94 (195.23, 388.22) | 0.001 |
| **AUCG**           | 18.35 (17.65, 19.45) | 24.9 (22.28, 21.45) | 26.33 (24.33, 30.89) | 0.001 |
| **HOMA-IR**        | 1.17 (0.97, 1.44)  | 1.54 (1.01, 2.05) | 3.28 (2.56, 4.06) | 0.001 |
| **IL6 (pg/ml)**    | 3.93 (2.35, 5.89)  | 36.05 (32.5, 45.54) | 39.01 (34.19, 49.61) | 0.001 |
| **TNFα (ng/ml)**   | 15.20 (14.00, 17.57) | 63.42 (53.09, 68.59) | 60.66 (55.59, 67.88) | 0.001 |

Values are medians (25th, 75th percentiles)

WHR waist-to-hip ratio, AMH anti-Müllerian hormone, FAI the free androgen index, FBG fasting blood glucose, 2-hBG 2-h blood glucose, FINS fasting insulin, 2-h Ins 2-h plasma insulin after glucose overload, TG triglyceride, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, AUCI the area under the curve of insulin, AUCG the area under the curve of glucose, HOMA-IR the homeostasis model assessment of IR

*P* value: total PCOS compared to the control

a, b and c *p < 0.05, p < 0.01 and p < 0.001* as compared to the control

d, e and f *p < 0.05, p < 0.01 and p < 0.001* as compared to normal weight PCOS (BMI<25)

**TABLE 2** Partial correlations analysis of variables associated with circulating SFRP5 levels in study population
| Item                  | Plasma SFRP5 | Plasma SFRP5 (age-adjusted) | Plasma SFRP5 (age-BMI-adjusted) | Plasma SFRP5 (age-BMI-WHR-adjusted) |
|----------------------|--------------|-----------------------------|----------------------------------|---------------------------------------|
|                      | r            | P-value                     | r                               | P-value                               |
| Age(years)           | 0.174        | 0.083                       | -0.524                          | 0.001                                 |
| BMI(Kg/m²)           | -0.492       | 0.001                       | -0.524                          | 0.001                                 |
| WHR                  | -0.271       | 0.006                       | -0.296                          | 0.003                                 |
| AMH(ng/ml)           | 0.501        | 0.001                       | -0.498                          | 0.001                                 |
| FAI                  | -0.566       | 0.001                       | -0.560                          | 0.001                                 |
| FINS(Uiu/ml)         | -0.452       | 0.001                       | -0.464                          | 0.001                                 |
| 2-h INS(Uiu/ml)      | -0.450       | 0.001                       | -0.459                          | 0.001                                 |
| FBG(mmol/l)          | -0.510       | 0.001                       | -0.568                          | 0.001                                 |
| 2-hBG(mmol/l)        | -0.444       | 0.001                       | -0.484                          | 0.001                                 |
| HOMA-IR              | -0.484       | 0.001                       | -0.505                          | 0.001                                 |
| IL6(pg/ml)           | -0.550       | 0.001                       | -0.572                          | 0.001                                 |
| TNFα(ng/ml)          | -0.708       | 0.001                       | -0.707                          | 0.001                                 |

**TABLE 3** Multiple linear regression analysis of variables associated with plasma SFRP5 levels in all subjects studied.
| Variable | Multiple |
|----------|----------|
|          | Beta     | P-value |
| BMI      | -0.121   | 0.664   |
| AMH      | -0.013   | 0.241   |
| FAI      | -0.216   | 0.041   |
| FBG      | -0.112   | 0.206   |
| 2-h BG   | 0.007    | 0.940   |
| IL6      | -0.266   | 0.046   |
| TNFα     | -0.308   | 0.033   |

TABLE 4 Multiple logistic regression analysis of SFRP5 for the diagnosis of PCOS

|                  | OR   | 95% CI       | P-value |
|------------------|------|--------------|---------|
| Total PCOS       | 0.818| 0.691-0.968  | 0.019   |
| PCOS Subgroup(AMH<4.7ng/ml) | 0.818| 0.692-0.968  | 0.019   |

TABLE 5 Baseline demographic and clinical characteristics between two treatment groups of clomiphene-metformin combination
TABLE 6 Comparison of the clinical outcomes between the two treatment groups of clomiphene-metformin combination

| Item                                                   | Group I (Clomiphene and Metformin) | Group II (Clomiphene alone) | P-value |
|--------------------------------------------------------|------------------------------------|-----------------------------|---------|
| N                                                      | 37                                 | 36                          |         |
| Age (years)                                            | 28.86±0.53                         | 27.36±0.65                  | 0.08    |
| BMI (Kg/m²)                                            | 25.13±0.36                         | 25.08±0.30                  | 0.91    |
| Duration of infertility (years)                        | 2.17±0.2277                        | 1.911±0.2116                | 0.42    |
| Spontaneous menstrual cycle interval (months)          | 3.42±0.38                          | 2.66±0.34                   | 0.14    |
| Menstrual flow length (days)                           | 6.62±0.55                          | 6.53±0.53                   | 0.90    |
| HbA1c (%)                                              | 5.79±0.04                          | 5.74±0.05                   | 0.53    |
| HOMA-IR                                                | 3.30(2.56, 4.49)                   | 3.42(2.78, 3.91)            | 0.72    |

| Item                                                   | Group I (Clomiphene and Metformin) | Group II (Clomiphene alone) | P-value |
|--------------------------------------------------------|------------------------------------|-----------------------------|---------|
| N                                                      | 37                                 | 36                          |         |
| Ovulation rate (%)                                     | 67.6(25)                           | 28.6(8)                     | <0.0001 |
| days for follicular development                        | 20.62±1.34                         | 26.69±1.29                  | 0.0017  |
| Endometrial thickness (mm)                             | 8.34±0.34                          | 8.15±0.27                   | 0.6663  |
| Number of dominant follicles (>14 mm)                  | 1.76±0.28                          | 0.53±0.20                   | 0.0007  |
| Serum estradiol on day of HCG (pg/mL)                  | 564.6±116.2                        | 270.4±62.0                  | 0.0287  |
| HCG positive rate (%)                                  | 37.8(14)                           | 19.4(7)                     | 0.1208  |
| Clinical pregnancy rate (%)                            | 29.7(11)                           | 8.3(3)                      | 0.0352  |
| Miscarriage rate (%)                                   | 21.4(3)                            | 57.1(4)                     | 0.1564  |
| Multiple pregnancy rate (%)                            | 18.2(2)                            | 33.3(1)                     |         |
Figure 1

ROC curve analysis of SFRP5 for total PCOS. In all PCOS population, the SFRP5 cut-off value was 46.13 ng/ml (AUC 0.960; 95% CI 0.900-0.989; P < 0.0001) to identify PCOS with a sensitivity of 88.06% and specificity of 96.87%. The AMH cut-off value was 3.23 ng/ml (AUC 0.968; 95% CI 0.912-0.993; P < 0.0001) with a sensitivity of 98.51% and specificity of 90.62%. The AUC of combination of SFRP5 and AMH was 0.980 with a sensitivity of 91.04% and specificity of 100% (95% CI 0.930-0.998; P < 0.0001). AUC: area under the curve, ROC: receiver operating characteristic analysis.
Figure 2

ROC curve analysis of SFRP5 for PCOS with AMH < 4.7ng/ml. In PCOS with AMH < 4.7ng/ml, the SFRP5 cut-off value was 42.69 ng/ml (AUC, 0.955; 95% CI 0.864-0.992; P < 0.0001) to identify PCOS with a sensitivity of 82.61% and specificity of 96.97%. AUC: area under the curve, ROC: receiver operating characteristic analysis